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Summary
Background Yellow fever cases are under-reported and the exact distribution of the disease is unknown. An effective 
vaccine is available but more information is needed about which populations within risk zones should be targeted to 
implement interventions. Substantial outbreaks of yellow fever in Angola, Democratic Republic of the Congo, and 
Brazil, coupled with the global expansion of the range of its main urban vector, Aedes aegypti, suggest that yellow fever 
has the propensity to spread further internationally. The aim of this study was to estimate the disease’s contemporary 
distribution and potential for spread into new areas to help inform optimal control and prevention strategies.
Methods We assembled 1155 geographical records of yellow fever virus infection in people from 1970 to 2016. We 
used a Poisson point process boosted regression tree model that explicitly incorporated environmental and biological 
explanatory covariates, vaccination coverage, and spatial variability in disease reporting rates to predict the relative 
risk of apparent yellow fever virus infection at a 5 × 5 km resolution across all risk zones (47 countries across the 
Americas and Africa). We also used the fitted model to predict the receptivity of areas outside at-risk zones to the 
introduction or reintroduction of yellow fever transmission. By use of previously published estimates of annual 
national case numbers, we used the model to map subnational variation in incidence of yellow fever across at-risk 
countries and to estimate the number of cases averted by vaccination worldwide.
Findings Substantial international and subnational spatial variation exists in relative risk and incidence of yellow fever 
as well as varied success of vaccination in reducing incidence in several high-risk regions, including Brazil, Cameroon, 
and Togo. Areas with the highest predicted average annual case numbers include large parts of Nigeria, the Democratic 
Republic of the Congo, and South Sudan, where vaccination coverage in 2016 was estimated to be substantially less 
than the recommended threshold to prevent outbreaks. Overall, we estimated that vaccination coverage levels 
achieved by 2016 avert between 94 336 and 118 500 cases of yellow fever annually within risk zones, on the basis of 
conservative and optimistic vaccination scenarios. The areas outside at-risk regions with predicted high receptivity to 
yellow fever transmission (eg, parts of Malaysia, Indonesia, and Thailand) were less extensive than the distribution of 
the main urban vector, A aegypti, with low receptivity to yellow fever transmission in southern China, where A aegypti 
is known to occur.
Interpretation Our results provide the evidence base for targeting vaccination campaigns within risk zones, as well as 
emphasising their high effectiveness. Our study highlights areas where public health authorities should be most 
vigilant for potential spread or importation events.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The global spread of mosquito-borne viruses such as 
dengue, chikungunya, West Nile virus, and Zika virus 
during recent decades1 highlights the urgent need 
to better understand both contemporary arbovirus 
distributions and their potential to spread into new areas. 
Substantial outbreaks of yellow fever in Angola, the 
Democratic Republic of the Congo (DR Congo), and 
Brazil in the past 2 years,2 combined with the global 
distribution of the main urban vector Aedes aegypti, 
suggest that yellow fever has the potential to spread 
further internationally and increase its financial burden 
on health systems as well as its toll on population health.
Yellow fever is vaccine preventable, yet incomplete 
coverage means that the disease is still widely distributed 
in the tropics and subtropics of Latin America and Africa. 
Local transmission of yellow fever has never been reported 
in Asia, despite multiple opportunities for introduction 
and seemingly suitable ecological and climatic conditions.3
Multiple transmission cycles of yellow fever virus coexist 
with different mosquito genera serving as vectors in 
each cycle. The virus is principally maintained by a 
sylvatic transmission cycle involving non-human primate 
reservoirs, and human beings can sporadically be 
incidental hosts. When infected people introduce yellow 
fever virus into heavily populated areas with competent 
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vector populations and insufficient vaccination, the virus is 
transmitted from person to person via A aegypti, and large-
scale epidemics can occur. The spectrum of human clinical 
disease caused by yellow fever virus is broad, ranging from 
asymptomatic (unapparent) infections to fatal disease.4
The epidemiology of yellow fever on the African 
continent, where most cases and epidemics are reported, 
involves a mix of transmission cycles. In recent decades, 
almost all cases of yellow fever in Latin America arose 
from sylvatic cycles, with inter-human transmission only 
reported a handful of times since the early 1940s.4 Although 
eradication of yellow fever is not considered feasible 
because of its sylvatic reservoir, outbreak control is 
achievable because of the availability of a safe, low cost, 
and effective vaccine. Since the vaccine became available in 
1937, the combination of vaccination and vector control 
strategies has led to a notable reduction in disease burden 
at some locations and times.5
The outbreak that started in Luanda, Angola, in 
December, 2015, developed into the largest and most 
widespread outbreak of yellow fever reported in Africa in 
more than 20 years.6 In March, 2016, several unvaccinated 
Chinese workers with yellow fever virus infection returned 
to China from the outbreak zone in Angola, which, 
alongside the depletion of global emergency vaccine 
stockpiles, raised concerns that yellow fever would gain an 
uncontrollable foothold in east and southeast Asia.7 
Fortunately, these importation events occurred in Beijing, 
Shanghai, and Fujian, where A aegypti is not established, 
and no secondary cases resulting from local transmission 
were detected.8
Informing vaccination and other control strategies for 
yellow fever requires an improved evidence base for 
identifying the most vulnerable populations. Risk mapping 
for yellow fever occurrence in areas at risk of transmission 
has previously been done at national and subnational 
levels,5,9,10 but the distribution of the disease within these 
areas remains poorly characterised. For areas outside the 
defined risk zones,9 the most recent efforts to identify 
populations at risk have been based on the distribution of 
A aegypti.11 Although presence of the vector is necessary for 
transmission, many other factors contribute towards the 
establishment and maintenance of transmission.12
In this study, we modelled subnational variation in 
risk of yellow fever across all risk zones and predicted 
receptivity to yellow fever virus transmission outside risk 
areas, using a model that is based on yellow fever infection 
data, vaccination coverage rates, and a range of environ-
mental and biological covariates.
Methods
Overview
We collated and georeferenced reports of symptomatic 
yellow fever virus infection in people for the 47-year period 
from 1970 to 2016. Records before 1970 were not included 
because we aimed to map the contemporary spatial 
Research in context
Evidence before this study
We searched PubMed on Dec 13, 2017, using the search terms 
“yellow fever” [All Fields] AND (“geograph*” [All Fields] OR 
“spati*” [All Fields]) without any date or language restrictions. 
This search returned 267 articles, of which seven contained 
information about the existing or potential geographical 
distribution of yellow fever risk. Five studies quantified yellow 
fever risk at national levels as well as at first or second 
administrative subnational units, or by ecological zone for a 
subset of countries; however, such results might mask 
considerable differences in yellow fever risk at more local 
levels. In 2006, Rogers and colleagues mapped yellow fever 
risk across both Africa and South America, as well as predicted 
climatic suitability for transmission outside these regions. This 
study analysed yellow fever data up to 2005, did not provide 
any estimate of spatial variation in disease incidence, 
or account for vaccination. An analysis of yellow fever data up 
to 2011 evaluated the impact of yellow fever vaccination in 
Africa, but the application of these findings might be limited 
in more recent years, and for other regions that have yellow 
fever epidemics (eg, Amazon basin). WHO has also done 
yellow fever risk assessments for high-risk and middle-risk 
African countries to identify regions most vulnerable to 
epidemics. To date, no study has quantified yellow fever risk or 
incidence across global risk zones at a high geospatial 
resolution, or evaluated potential for receptivity to yellow 
fever in areas outside current risk zones.
Added value of this study
We used 1155 records of human yellow fever virus infection from 
1970 to 2016 to generate a novel model of incidence of yellow 
fever at a 5 × 5 km resolution for 47 countries across risk zones. 
We estimated potential receptivity to yellow fever transmission in 
all countries that are currently outside of defined risk zones. This 
work incorporated the most contemporary data on occurrence of 
yellow fever, and the chosen modelling approach allowed the 
inclusion of vaccination coverage rates, variation in disease 
reporting effort, mechanistic knowledge of suitability for vectors, 
distribution maps for reservoir and vector species, and a range of 
covariate data on land cover.
Implications of all the available evidence
Our work furthers understanding of the contemporary global 
distribution of yellow fever, and the potential for its introduction 
and establishment into new regions. These results provide a 
current evidence base to prioritise areas for vaccination and 
surveillance programmes in present risk zones (such as parts of 
Nigeria, the Democratic Republic of the Congo, and South Sudan), 
and highlight areas where public health authorities should be 
most vigilant for potential spread or importation events 
(including Central America, southeast Asia, and eastern Brazil).
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distribution of yellow fever, and this timepoint coincides 
with the re-infestation of Latin America with A aegypti 
following 50 years of eradication efforts,13 and the cessation 
of organised large-scale yellow fever vaccination activities 
in west Africa and central Africa.5 We fitted a Poisson point 
process boosted regression tree (BRT) model to the 
database of yellow fever disease reports along with a range 
of environmental and socioeconomic variables postulated 
to influence yellow fever transmission. By explicitly 
accounting for population density, spatial variation in 
disease reporting rates, and vaccination coverage, we 
estimated the relative risk of apparent infection for each 
5 × 5 km grid square across risk zones (47 countries across 
the Americas and Africa). To map within-country variation 
in annual incidence, we used previously published national 
case estimates from the Global Burden of Diseases, 
Injuries, and Risk Factors Study 2015 (GBD 2015).14 The 
incidence map was averaged over 47 years to visualise 
spatial variation without the large temporal fluctuations 
seen for yellow fever. Finally, the fitted model for relative 
infection risk was used to predict areas of receptivity to 
yellow fever virus transmission beyond contemporary risk 
zones. A schematic overview of the process we followed is 
provided in the appendix (p 2).
Dataset
We assembled a database of locations where at least one 
laboratory-confirmed symptomatic human infection of 
yellow fever virus had been reported in any given year. This 
information was extracted from various sources including 
online sources, peer-reviewed literature, and WHO 
reports. Data from online sources were collated by the 
automated HealthMap system, as described elsewhere.15 
Spatial coordinates were assigned to each reported site of 
infection, only including sites where infections were 
diagnosed by serological, PCR-based, or other genetic 
detection techniques. For locations smaller than 5 × 5 km 
in area (points), only the latitude and longitude were 
recorded. The remaining sites (polygons) were assigned an 
administrative area code (eg, for a province or district). The 
final dataset included 1155 records, comprising 751 point 
locations and 404 polygon locations (figure 1). Details on 
the assembly of the occurrence dataset can be found in the 
appendix (pp 2–3).
Vaccination coverage and population density data
To account for the effects of yellow fever vaccination in 
our temporally static model of yellow fever infection risk, 
we required an estimate of the average susceptible 
population size across the study time period. To calculate 
this temporal average, we used vaccination coverage 
estimates for every 5 years from 1970 to 2016 (for which 
details can be found elsewhere),16 and a combination of 
WorldPop Project,17 Gridded Population of the World,18 
and UN World Population Prospects human population 
density data.19 Details of this procedure are described in 
the appendix (pp 4–5).
Model explanatory covariates
Ten 5 × 5 km gridded data surfaces of a range of 
environmental and biological factors thought to affect 
transmission of yellow fever virus were used as potential 
explanatory covariates (table).20–25 Predictive species 
distribution maps of suspected reservoir species of non-
human primates in Africa and Latin America were 
generated using a previously described approach,26 and 
were included in the model as biological covariates. See 
appendix (pp 6–12) for further details regarding the 
construction of each covariate data surface and for plots 
of each surface.
Modelling approach
We fitted an inhomogeneous Poisson point process 
model to the dataset of yellow fever disease reports using 
a BRT model to characterise the expected number of 
observations per unit area. By explicitly accounting for 
human population density, vaccination coverage rate, 
and variable reporting effort, this model estimated the 
incidence of apparent infections in susceptible 
individuals (which can be interpreted as the individual 
risk of apparent infection), to within a constant of 
proportionality at each 5 × 5 km grid square across risk 
zones.9 The fitted model was then used to estimate 
receptivity to yellow fever transmission in areas outside 
contemporary risk zones. See appendix (pp 13–16) for 
details of model specification and fitting.
Calibration of raw model outputs
By considering the size of the susceptible population 
within each 5 × 5 km grid square (based on vaccination 
coverage levels in 2016), and applying continental 
calibration factors, we estimated the average annual 
number of cases across risk zones (averaged over the 
47-year study period). Calibration factors were calculated 
using the average annual number of cases (from 
1990 to 2015) estimated by GBD 201514 and a generalised 
linear model—ie, we used a continental-scale estimate 
of incidence to calculate case detection rate, which is 
not identifiable from occurrence data alone. Details 
of the calibration procedure are described in the 
appendix (pp 17–18). We generated calibration factors of 
155·15 (lower bound 44·27, upper bound 405·99) for 
Africa, and 38·95 for South America (lower bound 10·32, 
upper bound 108·20). The mean calibration factors were 
applied to the raw model output to map average annual 
incidence and case numbers.
Model validation
The model’s predictive performance within risk zones 
was assessed by spatially stratified ten-fold cross-validation 
and by calculating the predictive deviance of the model, 
which is the mismatch between the predicted number of 
occurrence records and the number observed. Cross-
validation was done for each bootstrap of the model, 
resulting in a bootstrapped estimate of the model’s 
See Online for appendix
For the HealthMap see 
http://www.healthmap.org
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predictive capacity. Details of the validation procedures 
and results are provided in the appendix (p 16).
Cases averted by vaccination
We estimated the average annual number of cases of 
yellow fever per pixel using estimated vaccination 
coverage rates in 2016, based on three vaccination 
targeting scenarios for historical campaigns: conserv-
ative (untargeted, biased); untargeted, unbiased; and 
optimistic (targeted).16 To estimate the average annual 
number of cases of yellow fever averted within risk zones 
by 2016 vaccination levels, the outputs of conservative 
and optimistic cases per pixel were compared with a 
fourth scenario assuming 100% of the population in 2016 
were susceptible to yellow fever virus infection (ie, 
vaccination coverage rates assumed to be zero). Because 
our model estimates the relative risk of yellow fever 
infection from 1970 to 2016, and therefore assumes a 
constant rate of yellow fever infection through time, 
these values represent the cases averted by 2016 
vaccination levels given the average annual infection 
rate, not the specific infection rate in 2016, and assuming 
constant exposure to a source of yellow fever virus 
infection.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Our model predicted substantial international and 
subnational spatial variation in individual infection risk 
Data source
Evergreen broadleaf forest, urban and built up, and cropland 
mosaics land cover classes (proportional)
MODIS land cover product25
Elevation Shuttle Radar Topography Mission20
Tasselled cap wetness, a measure of surface moisture (mean) Gap-filled MODIS satellite data21,22
Enhanced vegetation index (mean) Gap-filled MODIS satellite data21,22
Aedes aegypti temperature suitability index Brady et al (2014)23
A aegypti habitat suitability Kraemer et al (2015)24
Predictive species distribution of suspected reservoir 
non-human primates
Prepared for this project (appendix pp 9–12)
MODIS=moderate resolution imaging spectroradiometer. 
Table: Explanatory covariates included in the analysis
Polygon data
Point data
Risk zones
Figure 1: Yellow fever occurrence data provided to the model
Polygon and point locations of reports of human yellow fever virus infection from 1970 to 2016. Points represent yellow fever virus infections reported in locations 
smaller than 5 × 5 km in area, where only the latitude and longitude of the site were recorded. Polygons represent yellow fever virus infections reported in locations 
larger than 5 × 5 km in area, which were assigned an administrative area code (eg, province or district). Grey areas represent contemporary risk zones as defined by 
Jentes and colleagues.9
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for yellow fever (figure 2). This risk can be interpreted as 
the rate at which susceptible individuals are expected to 
acquire a symptomatic yellow fever virus infection in a 
given location. The underlying risk for yellow fever can 
therefore be high in locations with negligible population 
density or high vaccination coverage. Areas with highest 
predicted individual infection risk within Latin America 
included the Amazonian regions of Brazil (particularly 
Pará, Acre, and Roraima states), Bolivia, Colombia, 
Ecuador, French Guiana, Guyana, Peru, Suriname, 
and Venezuela. Within the African risk zone, the 
areas with highest predicted individual infection risk 
included several locations within Burkina Faso (Cascades 
and Sud-Ouest), Cameroon (Centre, Est, Littoral, 
Sud-Ouest, and Nord), Côte d’Ivoire (Savanes, Zanzan, 
and Montagnes), DR Congo (Sankuru, Maï-Ndombe, 
Équateur, Maniema, Mongala, Tshuapa, Kwilu, Nord-
Ubangi, Bas-Uele, Haut-Uele, Ituri, and Tshopo), Ghana 
(Northern and Upper West), Liberia (Bong, Gbarpolu, 
Grand Gedeh, Lofa, and Nimba), Republic of the Congo 
(Sangha), Sierra Leone (Eastern), Mali (Sikasso), and 
South Sudan (Jonglei). Model uncertainty in spatial 
predictions of individual infection risk for yellow fever is 
shown in figure 3; there is low uncertainty in predictions 
in most areas.
Considered together, the maps of individual infection 
risk, average annual incidence, and average annual cases 
(figure 2) highlight the effects of vaccination on incidence 
of yellow fever. For example, populations of Brazil, Bolivia, 
Venezuela, Guinea, Cameroon, and Togo have high 
predicted rates of underlying risk of yellow fever, but low 
predicted annual incidence, on the basis of vaccination 
coverage levels achieved by 2016 (appendix p 5).16 
Conversely, they also suggest that many populous regions, 
with patchy or limited vaccination coverage, have a high 
exposure risk to yellow fever virus infection and are poorly 
protected against transmission. For example, areas with 
the highest predicted average annual cases included large 
parts of DR Congo (Sankuru, Maï-Ndombe, Équateur, 
Mongala, Tshuapa, Kwilu, Nord-Ubangi, Sud-Ubangi, 
Bas-Uele, Haut-Uele, and Tshopo), Nigeria (South-West, 
South-East, South-South, and North-Central zones), and 
Figure 2: Predicted distribution of yellow fever within contemporary risk zones
(A) Predicted spatial variation in individual risk of yellow fever virus infection. 
(B) Predicted average annual incidence of yellow fever (99·8% of grid squares 
within the disease’s range were predicted to have fewer than eight cases per 
100 people per year, the highest predicted value was 20 cases per 100 people per 
year). (C) Average annual numbers of yellow fever cases (99·5% of grid squares 
within the disease’s range were predicted to have fewer than three cases per 
year, the highest predicted value was 109 cases per year). Continental calibration 
factors have been applied to the outputs in B and C, calculated from Global 
Burden of Diseases, Injuries, and Risk Factors Study 2015 estimates of national 
incidence averaged from 1990 to 2015 (see full details in the Methods and 
appendix pp 17–18),14 and use population vaccination coverage rates achieved in 
2016. All predictions were restricted to areas within the contemporary risk zones 
as defined by Jentes and colleagues9 and averaged over the 47-year study period 
from 1970 to 2016.
A
B
C
Individual apparent
infection risk
1
0
Cases per 100 people 
per year
≥8·0
≥4·2
≥0
Cases per year
≥3·0
≥1·6
≥0
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South Sudan (Jonglei, Eastern Nile, Western Nile, 
Terekeka, Yei River, and Jubek), as well as smaller areas 
within Côte d’Ivoire (Montagnes), Sierra Leone (Eastern), 
Ghana (Ashanti and Northern), Mali (Sikasso), Ethiopia 
(Amhara region and Southern Nations, Nationalities, and 
Peoples  [SNNP] region), and Uganda (Adjumani). For 
most of these locations, vaccination coverage in 2016 was 
estimated to be less than the 60–80% recommended by 
WHO to prevent outbreaks.10
Using the total average annual cases estimated by our 
model, we calculated that globally, between 94 336 and 
118 500 cases of yellow fever are averted each year by 
vaccination coverage rates achieved in 2016 (based on 
conservative and optimistic vaccination coverage scenarios, 
respectively). These numbers represent 33% to 42% of 
total predicted cases if vaccination coverage was zero 
across risk zones. The global totals represent between 
84 385 and 99 840 cases averted on the African continent 
(33% to 39% of total predicted cases) and between 9951 and 
18 660 cases within Latin America (36% to 68% of total 
predicted cases).
Outside contemporary risk zones, we predict high 
receptivity to yellow fever virus transmission across much 
of southeast Asia, where yellow fever has never been 
reported, including large areas of Cambodia, India, 
Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, 
the Philippines, Thailand, and Vietnam (figure 4). High 
receptivity is also predicted in several countries within 
Central and South America, contiguous with risk zones. 
Historically, yellow fever has been reported in many of 
these countries, such as Costa Rica, Guatemala, Honduras, 
Nicaragua, and Mexico.27 We predict low receptivity to 
yellow fever virus transmission in several  locations where 
A aegypti is known to be present, for example southern 
China and southern USA.
Discussion
The high resolution maps of risk and incidence of yellow 
fever produced in this study highlight the success of 
vaccination in reducing incidence in high-risk regions, 
including Brazil, Cameroon, and Togo. The maps also 
identify areas with high predicted average annual case 
numbers, where vaccination coverage in 2016 was less 
than the recommended threshold to prevent outbreaks, 
such as large parts of Nigeria, DR Congo, and 
South Sudan. These maps provide an evidence base 
to prioritise areas for vaccination and vector control 
programmes in current risk zones. Receptivity to yellow 
fever virus transmission in areas outside risk zones 
was also mapped, including areas where yellow fever 
has been controlled, such as Central America, or has 
never persisted, such as southern Asia. Our findings 
highlight areas where public health authorities should be 
most vigilant for potential spread or importation events. 
Figure 3: Map of model uncertainty
Estimated pixel-wise uncertainty in spatial predictions of individual risk of apparent yellow fever virus infection, based on standard deviation values calculated for 
each pixel across the model ensemble.
Uncertainty
Higher
Lower
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Furthermore, the areas of high receptivity near the edge 
of the current risk zone on the southeast coast of Brazil 
(states of Bahia, Minas Gerais, São Paulo, Espírito Santo, 
and Rio de Janeiro) reflect a need to geographically 
expand the existing risk limits because locally acquired 
cases have recently been reported in this area.28
Rogers and colleagues3 used discriminant analysis 
techniques to predict areas of climatic suitability for yellow 
fever within Asia, including eastern Thailand and parts of 
Malaysia and Indonesia. Building on their analysis, our 
model predicts more extensive receptivity to yellow fever 
virus transmission within these countries, as well as other 
parts of the continent. We have extended the work of 
Rogers and colleagues by fitting, to the most recent 
occurrence data, a model that has been demonstrated to 
perform well, accounts for bias in disease reporting rates, 
and incorporates vaccination coverage rates. Furthermore, 
our model includes mechanistic knowledge of habitat 
suitability for vectors, a range of covariate data on land 
cover, and distribution maps for reservoir and vector 
species. To our knowledge, this work is the first example 
of a disease niche modelling approach that incorporates 
vaccination coverage rates. Our results for Africa 
(33–39% of cases averted from 1970 to 2016) add to 
a previous analysis that estimated that vaccination 
campaigns averted the number of cases by 22% to 
31% from 1987 to 2011.5 Our study includes more recent 
(and historical) occurrence data, and overall highlights the 
differences between Latin America and Africa.
We included distributions of A aegypti and non-human 
primate hosts in our model, because countries where 
both exist are thought to be most vulnerable to the 
introduction and establishment of yellow fever virus.12 
Importation of the virus by an infected traveller could 
initiate an urban epidemic and, if suitable vector and 
reservoir species are present, subsequently trigger an 
enzootic transmission cycle, leading to a long-term 
infection risk for the local population.7 The present ease 
and frequency of international travel, compounded by 
poor enforcement of travel vaccination requirements, 
low levels of vaccination coverage in many at-risk 
regions,16 and existing vaccine shortages, raise serious 
Figure 4: Predicted receptivity to yellow fever transmission outside contemporary risk zones
Receptivity to yellow fever transmission in areas outside the contemporary risk zones, as defined by Jentes and colleagues9 and shown in light brown. No species 
known to be potential hosts of yellow fever virus persist in areas east of the Wallace line (faunal boundary).
Receptivity index
1
0
Wallace line
A
B C
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concerns of introduction of yellow fever virus into naive 
human populations, particularly in southern Asia.8
Yellow fever has both urban and sylvatic transmission 
cycles, and the spatial and temporal distribution of cases 
fluctuates substantially. The periodicity of yellow fever 
epidemic activity is driven in part by the rapid depletion 
and slow replenishment of susceptible hosts, as illustrated 
by upsurges at irregular intervals in parts of west and east 
Africa. Our model did not attempt to capture temporal 
and spatial spikes in cases of yellow fever; the focus was 
on predicting spatial variation in the underlying risk of 
infection. Our outputs represent the period from 
1970 to 2016, averaged over the large fluctuations that 
occur. Thus, the results might smooth over important 
secular trends across time, and our estimated incidence 
for a particular location will be different from the 2016 
incidence, or even a 5-year average. Indeed, the five most 
recently reported outbreaks of yellow fever began in areas 
of variable predicted risk. Additionally, since all reports of 
yellow fever virus infection in human beings were 
included in the model, irrespective of whether infection 
was the result of a sylvatic, intermediate, or urban 
transmission cycle, the model predicts apparent infection 
risk from any transmission cycle. The BRT model is 
capable of encompassing different relations in the data 
arising from these distinct transmission cycles, with the 
given covariates.
Our model predicts receptivity to yellow fever virus 
transmission based on the relation between locations 
where yellow fever has been reported from 1970 to 2016, 
and the values of environmental and biological covariates 
at those locations. For this reason, predictions of high 
receptivity in southeast Asia should be interpreted with 
caution. Potential variables that distinguish current risk 
zones in Africa and the Americas from A aegypti-inhabited 
areas of southeast Asia might be missing from our 
analysis. Indeed, most theories that have been used to 
explain the absence of yellow fever in Asia involve 
biological factors rather than climatic or environmental 
ones. These factors include cross-protection from other 
flaviviruses, lower competence of local populations of 
A aegypti, and competition between other flaviviruses 
within mosquito cells,29 none of which are included in our 
model. The strength of the BRT approach is in its predictive 
power and ability to fit complex non-linear functions, with 
the given covariates. It is not possible to use this type of 
analysis to identify causal associations between the 
covariates and suitability for disease transmission. It 
would not be appropriate to make further inferences as to 
why the pattern of high receptivity predicted by our model 
is more contracted than the distribution of yellow fever’s 
main urban vector, A aegypti, or to further speculate on 
reasons for the disease’s absence from Asia to date. Our 
work, however, highlights areas for future improvement in 
our understanding of yellow fever ecology.
Our study involved multiple stages of analysis, each 
containing potential sources of bias and uncertainty, much 
of which was difficult to account for or quantify. Each stage 
of the analytical process involved fitting a model to an 
independent, fixed dataset. Since each of these models was 
fitted to fixed data, not the output of previous models, it 
was not meaningful to propagate uncertainty through 
these steps. However, there were some steps where it was 
important to account for or report uncertainties. In fitting 
the model of risk for apparent yellow fever virus infection, 
uncertainty in the spatial locations of reported cases was 
propagated through the model via Monte Carlo simulation. 
Similarly, uncertainty in the final step of the analytical 
process—calibrating spatial predictions of yellow fever risk 
against GBD 2015 estimates of annual cases—was 
estimated and reflected in reported results.
High-quality spatial data on yellow fever are lacking, 
largely because of diagnostic complexity and limitations 
of health-care systems in many affected countries. 
Our occurrence dataset included human yellow fever 
virus infections confirmed via both genetic and serological 
diagnostic methods. As a result of cross-reactivity 
among flaviviruses, the precision of serological diagnostic 
techniques is limited, particularly when considering 
historical records. Additionally, we assumed that estimates 
of vaccination coverage, combined with data on population 
size, were proportional to the number of people 
susceptible to yellow fever virus infection. Translating 
maps of unvaccinated individuals into maps of susceptible 
people is complicated by the acquisition of immunity via 
natural infection, which is difficult to quantify. Modelling 
efforts will be improved as the volume and quality 
of geographical data on yellow fever increases, ideally 
using diagnostics that distinguish past infection from 
vaccination, and from other flavivirus infections. For now, 
the work presented here provides the best available 
evidence base for identifying populations most vulnerable 
to yellow fever.
To develop the most cost-effective vaccination strategies 
that prevent outbreaks and minimise adverse events, 
vaccination policy makers require a clear understanding 
of geographical disease risk. Within risk zones, our model 
improves understanding of geographical risk and comes 
at a time when current policies may require re-evaluation 
in view of the demonstrated inadequacy of emergency 
stocks and surge capacity of vaccine manufacture to meet 
the needs of the recent outbreak in Angola.7 Because the 
vector of urban yellow fever transmission also transmits 
dengue virus, chikungunya virus, Zika virus, and other 
human pathogens, the work presented here can also 
inform integrated vector control strategies.30 Beyond risk 
zones, our map of receptivity identifies areas where 
governments should consider the need for travellers to or 
from countries endemic for yellow fever to be vaccinated, 
under the framework of the International Health 
Regulations, as well as assessing their capabilities for early 
detection and intervention. If local transmission was to 
occur in these locations, the map additionally provides an 
evidence base for predicting and limiting its spread.
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